{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:21:39Z","timestamp":1788402099883,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-023-05239-y","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:02:35Z","timestamp":1697184155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Novel therapies for growth disorders"],"prefix":"10.1007","author":[{"given":"Despoina M.","family":"Galetaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Dauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"5239_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1515\/jpem-2017-0157","volume":"31","author":"S Mohseni","year":"2018","unstructured":"Mohseni S, Heydari Z, Qorbani M, Radfar M (2018) Adherence to growth hormone therapy in children and its potential barriers. J Pediatr Endocrinol Metab 31:13\u201320","journal-title":"J Pediatr Endocrinol Metab"},{"key":"5239_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4158\/EP13194.OR","volume":"20","author":"BK Ayd\u0131n","year":"2014","unstructured":"Ayd\u0131n BK, Aycan Z, S\u0131klar Z et al (2014) Adherence to growth hormone therapy: results of a multicenter study. Endocr Pract 20:46\u201351","journal-title":"Endocr Pract"},{"key":"5239_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40271-017-0237-9","volume":"10","author":"M Brod","year":"2017","unstructured":"Brod M, H\u00f8jbjerre L, Alolga SL, Beck JF, Wilkinson L, Rasmussen MH (2017) Understanding treatment burden for children treated for growth hormone deficiency. Patient 10:653\u2013666","journal-title":"Patient"},{"key":"5239_CR4","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1073\/pnas.89.10.4304","volume":"89","author":"FA Fares","year":"1992","unstructured":"Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I (1992) Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci USA 89:4304\u20134308","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5239_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/275063","volume":"2011","author":"F Fares","year":"2011","unstructured":"Fares F, Havron A, Fima E (2011) Designing a long acting erythropoietin by fusing three carboxyl-terminal peptides of human chorionic gonadotropin \u03b2 subunit to the N-terminal and C-terminal coding sequence. Int J Cell Biol 2011:275063","journal-title":"Int J Cell Biol"},{"key":"5239_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1530\/EJE-16-0748","volume":"176","author":"CJ Strasburger","year":"2017","unstructured":"Strasburger CJ, Vanuga P, Payer J et al (2017) MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults. Eur J Endocrinol 176:283\u2013294","journal-title":"Eur J Endocrinol"},{"key":"5239_CR7","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1210\/jc.2016-3547","volume":"102","author":"N Zelinska","year":"2017","unstructured":"Zelinska N, Iotova V, Skorodok J et al (2017) Long-acting C-terminal peptide-modified hGH (MOD-4023): results of a safety and dose-finding study in GHD children. J Clin Endocrinol Metab 102:1578\u20131587","journal-title":"J Clin Endocrinol Metab"},{"key":"5239_CR8","doi-asserted-by":"publisher","first-page":"e2717","DOI":"10.1210\/clinem\/dgac220","volume":"107","author":"CL Deal","year":"2022","unstructured":"Deal CL, Steelman J, Vlachopapadopoulou E et al (2022) Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab 107:e2717\u2013e2728","journal-title":"J Clin Endocrinol Metab"},{"key":"5239_CR9","doi-asserted-by":"crossref","unstructured":"Zadik Z, Zelinska N, Iotova V et al (2023) An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment. J Pediatr Endocrinol Metab 36:261\u20139","DOI":"10.1515\/jpem-2022-0359"},{"key":"5239_CR10","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1210\/clinem\/dgab529","volume":"106","author":"PS Thornton","year":"2021","unstructured":"Thornton PS, Maniatis AK, Aghajanova E et al (2021) Weekly lonapegsomatropin in treatment-na\u00efve children with growth hormone deficiency: the phase 3 height trial. J Clin Endocrinol Metab 106:3184\u20133195","journal-title":"J Clin Endocrinol Metab"},{"key":"5239_CR11","doi-asserted-by":"crossref","unstructured":"Alkhatib EH, Dauber A, Estrada DE, Majidi S (2023) Weekly growth hormone (lonapegsomatropin) causes severe transient hyperglycemia in a child with obesity. Horm Res Paediatr 1\u20135","DOI":"10.1159\/000530522"},{"key":"5239_CR12","doi-asserted-by":"crossref","unstructured":"S\u00e4vendahl L, Battelino T, Rasmussen MH et al (2023) Weekly somapacitan in GH deficiency: 4-year efficacy, safety and treatment\/disease burden results from REAL 3. J Clin Endocrinol Metab\u00a0","DOI":"10.1210\/clinem\/dgad183"},{"key":"5239_CR13","doi-asserted-by":"publisher","first-page":"e1847","DOI":"10.1210\/clinem\/dgz310","volume":"105","author":"L S\u00e4vendahl","year":"2020","unstructured":"S\u00e4vendahl L, Battelino T, Brod M et al (2020) Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial. J Clin Endocrinol Metab 105:e1847\u2013e1861","journal-title":"J Clin Endocrinol Metab"},{"key":"5239_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1210\/jcem-70-1-207","volume":"70","author":"JO J\u00f8rgensen","year":"1990","unstructured":"J\u00f8rgensen JO, M\u00f8ller N, Lauritzen T, Alberti KG, Orskov H, Christiansen JS (1990) Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab 70:207\u2013214","journal-title":"J Clin Endocrinol Metab"},{"key":"5239_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1046\/j.1365-2265.1996.00814.x","volume":"45","author":"T Laursen","year":"1996","unstructured":"Laursen T, M\u00f8ller J, J\u00f8rgensen JO, Orskov H, Christiansen JS (1996) Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients. Clin Endocrinol (Oxf) 45:333\u2013339","journal-title":"Clin Endocrinol (Oxf)"},{"key":"5239_CR16","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1210\/jcem-70-6-1616","volume":"70","author":"JO J\u00f8rgensen","year":"1990","unstructured":"J\u00f8rgensen JO, M\u00f8ller N, Lauritzen T, Christiansen JS (1990) Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. J Clin Endocrinol Metab 70:1616\u20131623","journal-title":"J Clin Endocrinol Metab"},{"key":"5239_CR17","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-15-0873","volume":"174","author":"DB Allen","year":"2016","unstructured":"Allen DB, Backeljauw P, Bidlingmaier M et al (2016) GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol 174:P1-9","journal-title":"Eur J Endocrinol"},{"key":"5239_CR18","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1530\/EC-18-0047","volume":"7","author":"G Johannsson","year":"2018","unstructured":"Johannsson G, Bidlingmaier M, Biller BMK et al (2018) Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocr Connect 7:R126\u2013R134","journal-title":"Endocr Connect"},{"key":"5239_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.637209","volume":"12","author":"KCJ Yuen","year":"2021","unstructured":"Yuen KCJ, Miller BS, Boguszewski CL, Hoffman AR (2021) Usefulness and potential pitfalls of long-acting growth hormone analogs. Front Endocrinol (Lausanne) 12:637209","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5239_CR20","doi-asserted-by":"crossref","unstructured":"Pampanini V, Deodati A, Inzaghi E, Cianfarani S (2022) Long-acting growth hormone preparations and their use in children with growth hormone deficiency. Horm Res Paediatr\u00a0","DOI":"10.1159\/000523791"},{"key":"5239_CR21","doi-asserted-by":"crossref","unstructured":"Lin Z, Shu AD, Bach M, Miller BS, Rogol AD (2022) Average IGF-1 Prediction for once-weekly lonapegsomatropin in children with growth hormone deficiency. J Endocr Soc 6:bvab168","DOI":"10.1210\/jendso\/bvab168"},{"key":"5239_CR22","doi-asserted-by":"crossref","unstructured":"Hoover-Fong J, Scott CI, Jones MC (2020) Health supervision for people with achondroplasia. Pediatrics 145","DOI":"10.1542\/peds.2020-1010"},{"key":"5239_CR23","unstructured":"Merchant NDA Shedding light: novel therapies for common disorders. Achondroplasia and growth disorders Accepted."},{"key":"5239_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1124\/jpet.114.218560","volume":"353","author":"DJ Wendt","year":"2015","unstructured":"Wendt DJ, Dvorak-Ewell M, Bullens S et al (2015) Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism. J Pharmacol Exp Ther 353:132\u2013149","journal-title":"J Pharmacol Exp Ther"},{"key":"5239_CR25","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","volume":"91","author":"F Lorget","year":"2012","unstructured":"Lorget F, Kaci N, Peng J et al (2012) Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet 91:1108\u20131114","journal-title":"Am J Hum Genet"},{"key":"5239_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa1813446","volume":"381","author":"R Savarirayan","year":"2019","unstructured":"Savarirayan R, Irving M, Bacino CA et al (2019) C-type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med 381:25\u201335","journal-title":"N Engl J Med"},{"key":"5239_CR27","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1124\/jpet.119.258251","volume":"370","author":"VM Breinholt","year":"2019","unstructured":"Breinholt VM, Rasmussen CE, Mygind PH et al (2019) TransCon CNP, a sustained-release C-type natriuretic peptide prodrug, a potentially safe and efficacious new therapeutic modality for the treatment of comorbidities associated with fibroblast growth factor receptor 3-related skeletal dysplasias. J Pharmacol Exp Ther 370:459\u2013471","journal-title":"J Pharmacol Exp Ther"},{"key":"5239_CR28","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.1111\/bcp.15369","volume":"88","author":"VM Breinholt","year":"2022","unstructured":"Breinholt VM, Mygind PH, Christoffersen ED et al (2022) Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug. TransCon CNP Br J Clin Pharmacol 88:4763\u20134772","journal-title":"TransCon CNP Br J Clin Pharmacol"},{"key":"5239_CR29","unstructured":"TransCon\u2122CNP ACcomplisHTrial Topline Results.\u00a0https:\/\/investors.ascendispharma.com\/static-files\/44b24b0c-f83d-48fa-aaef-9bdb768999d3"},{"key":"5239_CR30","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1172\/JCI83926","volume":"126","author":"D Komla-Ebri","year":"2016","unstructured":"Komla-Ebri D, Dambroise E, Kramer I et al (2016) Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model. J Clin Invest 126:1871\u20131884","journal-title":"J Clin Invest"},{"key":"5239_CR31","doi-asserted-by":"crossref","unstructured":"Savarirayan R, De Bergua JM, Arundel P et al (2022) Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies. Ther Adv Musculoskelet Dis 14:1759720x221084848","DOI":"10.1177\/1759720X221084848"},{"key":"5239_CR32","unstructured":"PROPEL2 topline results (2023) https:\/\/investor.bridgebio.com\/static-files\/25c6cab1-cbec-4c6-96a6-067367e8e170"},{"key":"5239_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.7326\/0003-4819-149-9-200811040-00003","volume":"149","author":"R Nass","year":"2008","unstructured":"Nass R, Pezzoli SS, Oliveri MC et al (2008) Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 149:601\u2013611","journal-title":"Ann Intern Med"},{"key":"5239_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1067\/mcp.2001.116514","volume":"70","author":"E Codner","year":"2001","unstructured":"Codner E, Cassorla F, Tiulpakov AN et al (2001) Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther 70:91\u201398","journal-title":"Clin Pharmacol Ther"},{"key":"5239_CR35","doi-asserted-by":"crossref","unstructured":"Bright GM, Do MT, McKew JC, Blum WF, Thorner MO (2021) Development of a predictive enrichment marker for the oral GH secretagogue LUM-201 in pediatric growth hormone deficiency. J Endocr Soc 5:bvab030","DOI":"10.1210\/jendso\/bvab030"},{"key":"5239_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000524244","volume":"95","author":"GM Bright","year":"2022","unstructured":"Bright GM, Thorner MO (2022) A GH secretagogue receptor agonist (LUM-201) elicits greater GH responses than standard GH secretagogues in subjects of a pediatric GH deficiency trial. Horm Res Paediatr 95:76\u201381","journal-title":"Horm Res Paediatr"},{"key":"5239_CR37","unstructured":"Dauber A (2023) Growth response of oral LUM-201 in OraGrowtH210 and OraGrowtH212 trials in idiopathic pediatric growth hormone deficiency (iPGHD): combined analysis interim analysis data. ENDO Chicago"},{"key":"5239_CR38","doi-asserted-by":"publisher","first-page":"1211426","DOI":"10.3389\/fendo.2023.1211426","volume":"14","author":"L Seefried","year":"2023","unstructured":"Seefried L, Duplan MB, Briot K et al (2023) Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives. Front Endocrinol (Lausanne) 14:1211426","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"5239_CR39","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K et al (2014) Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 3(1):R13-30","journal-title":"Endocr Connect"},{"key":"5239_CR40","doi-asserted-by":"publisher","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","volume":"107","author":"LM Ward","year":"2022","unstructured":"Ward LM, Glorieux FH, Whyte MP et al (2022) Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia. J Clin Endocrinol Metab 107:e3241\u2013e3253","journal-title":"J Clin Endocrinol Metab"},{"key":"5239_CR41","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP et al (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393:2416\u20132427","journal-title":"Lancet"},{"issue":"11","key":"5239_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10672","volume":"6","author":"M Gadion","year":"2022","unstructured":"Gadion M, Herv\u00e9 A, Herrou J et al (2022) Burosumab and dental abscesses in children with X-linked hypophosphatemia. JBMR Plus 6(11):e10672","journal-title":"JBMR Plus"},{"key":"5239_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Simmons JH, Moseley S et al (2019) Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol 7:93\u2013105","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5239_CR44","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1210\/jc.2018-02335","volume":"104","author":"CE Hofmann","year":"2019","unstructured":"Hofmann CE, Harmatz P, Vockley J et al (2019) Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study. J Clin Endocrinol Metab 104:2735\u20132747","journal-title":"J Clin Endocrinol Metab"},{"key":"5239_CR45","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","volume":"121","author":"PS Kishnani","year":"2019","unstructured":"Kishnani PS, Rockman-Greenberg C, Rauch F et al (2019) Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone 121:149\u2013162","journal-title":"Bone"},{"key":"5239_CR46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1126\/science.1190354","volume":"329","author":"T Hidvegi","year":"2010","unstructured":"Hidvegi T, Ewing M, Hale P et al (2010) An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 329:229\u2013232","journal-title":"Science"},{"key":"5239_CR47","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1172\/JCI93094","volume":"127","author":"LA Mullan","year":"2017","unstructured":"Mullan LA, Mularczyk EJ, Kung LH et al (2017) Increased intracellular proteolysis reduces disease severity in an ER stress-associated dwarfism. J Clin Invest 127:3861\u20133865","journal-title":"J Clin Invest"},{"key":"5239_CR48","unstructured":"MCDS Therapy EU Horizon (2020) Project at https:\/\/mcds-therapy.eu\/"},{"issue":"6","key":"5239_CR49","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1515\/jpem-2021-0045","volume":"34","author":"C Kamoun","year":"2021","unstructured":"Kamoun C, Hawkes CP, Grimberg A (2021) Provocative growth hormone testing in children: how did we get here and where do we go now? J Pediatr Endocrinol Metab 34(6):679\u2013696","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"2","key":"5239_CR50","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.5199","volume":"175","author":"A Tidblad","year":"2021","unstructured":"Tidblad A, Bottai M, Kieler H et al (2021) Association of childhood growth hormone treatment with long-term cardiovascular morbidity. JAMA Pediatr 175(2):e205199","journal-title":"JAMA Pediatr"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05239-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-023-05239-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05239-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T06:51:13Z","timestamp":1710917473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-023-05239-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":50,"alternative-id":["5239"],"URL":"https:\/\/doi.org\/10.1007\/s00431-023-05239-y","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"18 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}